PharmaLex Denmark A/S: Financial statements 2012
CVR: 18652439
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
PharmaLex Denmark A/S (CVR 18652439) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK 9,854,675 and a net result of DKK 2,321,466. Equity in the 2012 report amounted to DKK 7,166,090. The solvency ratio was 45.3%.
- Gross Profit
- DKK 9,854,675
- Profit/Loss
- DKK 2,321,466
- Equity
- DKK 7,166,090
- Total Assets
- DKK 15,810,529
Official annual report
Keep an eye on PharmaLex Denmark A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of June 26, 2012, Henrik Kagenow has joined the board of directors of PharmaLex Denmark A/S.
As of June 26, 2012, Niels Bjerregaard has left the board of directors of PharmaLex Denmark A/S.
About PharmaLex Denmark A/S
PharmaLex Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 1995. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named JACOBSEN PHARMA CONSULTANCY A/S and SLP NR. 11.026 A/S. The management consists of Åsa Pihlblad. The board consists of Christopher Gauglitz (chair), Carlos Antonio Santaflorentina Juanino and Åsa Pihlblad. The company is owned by Pharmalex Nordic ApS. The company has 15 employees (2026). In 2025, the company reported a gross profit of DKK 17,235,093 and a net result of DKK -1,712,095 compared with DKK 1,745,746 the year before. Equity in the 2025 report amounted to DKK 2,761,242.